List of Certificates of Suitability (CEPs) for Active Pharmaceutical Ingredients (APIs) issued to UQUIFA by EDQM. Original Data: EDQM Database

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Spain
Address
Address
C/ Mallorca 262, 3rd floor, Barcelona 08008
Telephone
Telephone
+34 934 674 810

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

CPhI Worldwide, Milan

CPhI Worldwide, Milan

Not Confirmed

envelop Contact Supplier

CPhI Worldwide, Milan

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

INTERVIEW #SpeakPharma

[Sponsored by another company]
“We’re unlocking life-changing potential in complex molecules, without sacrificing time to market”
This week, SpeakPharma interviews Mike Riley, CEO of Veranova, a leading contract development and manufacturing organization (CDMO) confidently mastering complex APIs as it marks its second year as an independent company. Riley discusses Veranova’s key achievements, including a US$ 30 million investment in their Devens, Massachusetts (US) site to expand capabilities in antibody-drug conjugates (ADCs) and highly potent APIs (HPAPIs), and how it is navigating the increasing complexity of molecules. 🔑 HIGHLIGHTS// Veranova’s key achievements / navigating the increasing complexity of molecules Veranova is celebrating its second year as a stand-alone company. Can you share Veranova’s key milestones and achievements in its first two years? We have achieved incredible milestones over the last two years, thanks to the dedication and hard work of our team. Our first 12 months focused on establishing ourselves as an independent CDMO by building on the 50 years of expertise that we brought with us. In addition, we expanded our capabilities and applied a more agile approach available to us as a company singularly focused on life sciences. This has allowed us to move into our second year with clear and strategic goals for generating growth in our sites, people, capabilities, and offerings. Since being appointed as CEO in May 2023, I’ve had the pleasure of witnessing some exciting growth milestones of my own. Most recently, we announced an estimated US$ 30 million investment in our Devens, Massachusetts, site. This expansion will allow us to build upon existing development and manufacturing capabilities in ADCs and HPAPIs that will address the growing demand for strong US-based capacity in these key drug modalities. We also appointed our Advisory Board, thereby bolstering Veranova’s in-house expertise. Made up of four distinguished leaders in pharma and biopharma – including Dr. Carolyn Bertozzi, the 2022 Nobel Laureate in Chemistry – the Board has provided thought-leadership, guidance and expertise as we develop and execute our strategic growth and ideas. We were also proud to be recognized as one of the Society of Chemical Manufacturers and Affiliates’ 12 companies for industry-leading safety programs in 2023 and as a part of the Medicine Maker’s Power List in 2024. 🔑 HIGHLIGHTS// US$ 30 million investment in our Devens, Massachusetts, site / appointed our Advisory Board Molecules are becoming increasingly complex. Can you elaborate on how Veranova’s current capabilities are strategically designed to address this trend in the coming years? The pharmaceutical pipeline is witnessing an increasing number of complex and highly potent molecules. This trend is driven by the demand for more targeted, patient-centric therapeutics and the focus on innovative modalities such as ADCs and other bioconjugates. At Veranova, our expertise, world-class facilities, and scientific excellence enable us to provide our customers with the clarity and solutions needed to manage this development and manufacturing complexity and ultimately deliver the required treatments to customers and patients. Our people are key to this approach. We have an expert team ready to collaborate with customers at any point, from early development through large-scale commercial production. Our services include world-leading crystallization development, process development, and specialized manufacturing expertise for complex synthetic molecules, including those requiring chromatography capabilities. In many cases, we can provide all these under one roof. Our service offering to our customers is also based on the foundational element of strong quality and compliance systems. We operate multiple facilities approved by the US FDA, UK’s MHRA and other regulatory authorities and are continually focused on ways to strengthen our global quality management system. Looking ahead, we are focused on continually investing in our facilities and team to meet growing complexity, as evidenced by our recent announcement of new investment in our Devens site. This investment signals our commitment to providing state-of-the-art capacity and capabilities to enable these next-generation therapies to reach patients. It is a key milestone as we advance Veranova’s broader growth strategy. 🔑 HIGHLIGHTS// provide our customers with clarity and solutions / world-leading crystallization development / expertise for complex synthetic molecules / strong quality and compliance systems How is Veranova approaching the challenge of designing and manufacturing effective linker molecules for ADCs? As a leader in complex linker-payload synthesis, Veranova is committed to unlocking the life-changing potential of ADCs without letting their complexities slow down the development of much-needed cancer therapies. ADCs are intricate, multi-component molecules that require extensive expertise and agile collaboration to overcome unique development challenges. With over a decade of experience in ADC linker-payload systems, we have developed the ability to anticipate challenges and avoid common pitfalls. The ADC linker-payload components are complex structures that are difficult to crystallize and require specialized high-potent handling. Veranova’s differentiated combination of world-leading crystallization development capabilities, complex synthesis experience, chromatography expertise and high-potent-handling experience put us in a unique position to solve these challenges for customers and speed their products to the clinic. We prioritize getting it right the first time, minimizing change orders and ensuring high-quality results. We have developed a robust phase-appropriate strategy that is backed by state-of-the-art analytical equipment and regulatory procedures to ensure our partners can rapidly progress their ADC projects from pre-clinical to commercialization. 🔑 HIGHLIGHTS// unlocking the life-changing potential of ADCs / ensuring our partners can rapidly progress their ADC projects Can you specify how Veranova is using artificial intelligence (AI) to optimize manufacturing processes that can reduce costs and environmental footprint as well as speed up development? In May 2024, Veranova announced a partnership with Phorum.AI to leverage AI to optimize pharmaceutical manufacturing processes. This collaboration aims to enable the rapid development of processes that can drive efficiency and reduce costs while maximizing environmental sustainability. Our goal is to combine Veranova’s extensive empirical manufacturing dataset of owned APIs and drug master files with Phorum.AI’s computational chemistry engine in order to create a more powerful process-development tool for the benefit of Veranova’s and Phorum’s customers. At Veranova, we are constantly looking to employ innovative technologies and approaches to improve efficiency, accelerate time to market and reduce environmental footprint. We have the means to work with a variety of partners who have unique project requirements, without sacrificing time to market.  🔑 HIGHLIGHTS// partnership with Phorum.AI / create a more powerful process-development tool / improve efficiency, accelerate time to market and reduce environmental footprint

Impressions: 1659

https://www.pharmacompass.com/speak-pharma/we-re-unlocking-life-changing-potential-in-complex-molecules-without-sacrificing-time-to-market

#SpeakPharma With Veranova
10 Sep 2024

VLOG #PharmaReel

[Sponsored by another company]

DATA COMPILATION #PharmaFlow

[Sponsored by another company]
Excipient Market Overview: Roquette, Seqens, Evonik make strategic moves; new guidelines deal with contamination
The pharmaceutical industry has long recognized the critical role excipients or inactive ingredients play in drug formulation and delivery. Excipients can comprise up to 90 percent of a medicine's total ingredients and serve crucial functions as binders, disintegrants, coatings, preservatives, colors, and flavorings. According to recent market research, the pharmaceutical excipients market was valued at US$ 9.27 billion in 2023. It is growing at a compound annual growth rate (CAGR) of 7.03 percent and is projected to reach US$ 18.48 billion by 2032. The main factors driving market growth is an increased demand for multifunctional excipients, coupled with the expanding use of generic medications. The development in the biologics sector and advancements in nanotechnology are also contributing significantly to market growth. Major excipient providers include BASF, Evonik, Merck KGaA owned MilliporeSigma, Gangwal Healthcare, Roquette Frères, DuPont, Croda International, Seqens, Boai NKY Pharmaceuticals, PMC Isochem, Minakem, Kewpie Corporation, Ashland Global, SPI Pharma, Pfanstiehl, Nanjing Well Pharmaceutical, ICE Pharma, Anhui Ribobay Pharmaceutical and Nippon Fine Chemical.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) WHO, India’s CDSCO tighten regulations; new GMP guidelines implemented to curb contamination Last year, the World Health Organization (WHO) issued a health alert linking at least 300 child deaths in the Gambia, Uzbekistan, and Indonesia to the ingestion of contaminated cough syrups containing unacceptable levels of diethylene glycol (DEG) and ethylene glycol (EG). In response to the tragic events, the WHO released two draft appendices to its guideline on good manufacturing practices (GMPs) for excipients this year. Manufacturers are now required to use suitable risk assessment tools to identify and mitigate potential hazards.  Since India-made cough syrups had been linked to the deaths, India’s drug regulator — Central Drugs Standard Control Organization (CDSCO) — took steps to prevent contamination, and advised drugmakers to only use pharmaceutical-grade excipients from approved sources. Furthermore, the Indian Health Ministry proposed amendments to the Drugs and Cosmetics Rules, 1945 to include details of excipients on drug labels. While listing all excipients on every strip of medicine may be challenging, the ministry suggested mentioning those causing hypersensitivity on the label. Applicants now mandatorily need to submit evidence of stability and safety of excipients. These regulatory developments have significant implications for excipient manufacturers and pharmaceutical companies worldwide. Leading pharmaceutical excipient firms like Gangwal Healthcare, Sigachi Industries, and Nitika Pharmaceuticals are well-positioned to meet these heightened quality and safety standards, given their long-standing commitment to producing high-quality, compliant excipients.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Roquette buys IFF’s pharma unit for US$ 2.85 bn; Evonik opens new spray-drying facility in Darmstadt In a significant industry move, France-based Roquette entered into an agreement to acquire IFF's pharma solutions business in a deal valued at US$ 2.85 billion. This acquisition is set to rebalance family-owned Roquette’s portfolio around health and nutrition. The deal is expected to accelerate Roquette’s growth and significantly strengthen its presence in the excipients market. Evonik has opened a new facility for drying aqueous dispersions of its Eudragit polymers at its site in Darmstadt, Germany. The facility will help Evonik meet increasing demand from drugmakers for its oral drug delivery solutions. The plant uses green energy solutions. The company has also partnered University of Mainz to commercialize a new class of polyethylene glycols (PEG) lipids for nucleic acid delivery. Evonik’s Health Care business has been growing its nucleic acid drug and vaccine delivery portfolio.  Germany’s Johannes Gutenberg University of Mainz was the first to develop randomized polyethylene glycols (rPEGs). This collaboration aims to expand Evonik’s toolbox of technologies for nucleic acid-based medicines, offering an improved immunogenicity profile for lipid nanoparticle carriers used in mRNA vaccines and therapeutics. Asahi Kasei made significant strides in addressing a pressing industry concern that emerged in 2018 when potentially carcinogenic nitrosamine impurities were detected in several pharmaceuticals. Guided by regional authorities, such as the European Medicines Agency and the US Food and Drug Administration, the pharmaceutical industry has been carrying out extensive assessments and research to identify the cause of these impurities. In response to this challenge, Asahi Kasei developed its Ceolus microcrystalline cellulose with extremely low nitrite levels. The Japanese company achieved nitrite concentrations of 0.1 micrograms per gram or less, which is equivalent to 0.1 parts per million (ppm). The company also started full commercial operation of its second manufacturing facility for Ceolus in Japan, enhancing supply capacity and stability. JRS Pharma and Gujarat Microwax opened a state-of-the-art cotton-based croscarmellose sodium plant in Mehsana, Gujarat (India). This facility aims to produce high-quality excipients that meet global standards, potentially reducing India's dependency on imports and boosting its presence in the global excipient market. The Indian excipient industry accounts for less than 1 percent of the global market share.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Seqens to advance innovative polymer; biologics, personalized medicine create demand for specialized excipients Recent industry collaborations highlight the ongoing innovation in novel excipients. France’s Seqens, with over 20 years of polymer development experience, was chosen by Pleryon Therapeutics to advance its leading osteoarthritis candidate – an innovative GMP polymer. This collaboration leverages Seqens’ newly expanded and modernized cGMP plant in Aramon, France, demonstrating the industry’s commitment to investing in advanced manufacturing capabilities for novel excipients.  The rise of biologics and personalized medicine has created a demand for specialized excipients capable of stabilizing complex molecules and enabling targeted drug delivery. Roquette’s launch of Lycagel Flex, a hydroxypropyl pemix for nutraceutical and pharmaceutical softgel capsules, exemplifies this trend. Built on Roquette’s market-first Lycagel pea starch technology, this plant-based alternative to gelatin offers manufacturers the flexibility to customize formulations for a range of production and end-user needs. The innovative pea starch foundation also underscores the industry’s move towards sustainable bio-based excipients. The trend towards patient-centric drug development has also influenced excipient innovation. Excipients that can improve palatability, ease of swallowing, or enable novel dosage forms (such as orally disintegrating tablets) are in high demand. For example, IFF brought a super disintegrant Ac-Di-Sol, that supports faster disintegration and drug dissolution in oral disintegrating tablets, improving patient experience.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Our view The heightened regulatory scrutiny on excipients due to product contamination incidents has created a high risk perception and uncertainty around the regulatory acceptance of novel excipients. That said, novel excipients are central to the development of new drug modalities and therapies. Going forward, sustainability will also become an increasingly important factor in excipient selection and development. As the industry innovates towards biologics, personalized therapies, and patient-centric formulations, the role of high-quality, multifunctional excipients will only grow more vital in ensuring drug stability, bioavailability, and patient compliance. Companies that can navigate the complex regulatory landscape, invest in R&D, and offer high-quality, multifunctional excipients will be well-positioned to succeed in this evolving market.   

Impressions: 727

https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-seqens-evonik-make-strategic-moves-new-guidelines-deal-with-contamination

#PharmaFlow by PHARMACOMPASS
12 Sep 2024

NEWS #PharmaBuzz

read-more
read-more
Applying Agile methodologies in CDMOs
Applying Agile methodologies in CDMOs

14 May 2021

// EXPRESS PHARMA

https://www.expresspharma.in/applying-agile-methodologies-in-cdmos/

EXPRESS PHARMA
14 May 2021
External Communication - Covid-19
External Communication - Covid-19

15 Mar 2021

// PRESS RELEASE

http://www.uquifa.com/en/news/267-external-communication-covic-19

PRESS RELEASE
15 Mar 2021

https://www.elnacional.cat/ca/salut/esteve-uquifa-participen-fabricacio-remdesivir-gilead_525204_102.html

ELNACIONAL
24 Jul 2020

https://www.accessdata.fda.gov/cms_ia/importalert_189.html

FDA
22 Jul 2020

https://www.pharmacompass.com/pdf/news/uquifa-union-farmaceutica-sa-on-health-canada-inspection-list-1589346775.pdf

HEALTH CANADA
13 May 2020

https://www.business-standard.com/article/pti-stories/vivimed-s-uquifa-expects-euro-200-mn-revenues-in-4-yrs-118080100629_1.html

BUSINESS-STANDARD
23 Mar 2020

LISTED APIs

read-more
read-more
With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermedia...
With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.
blank

01

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

UQUIFA

With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.

About the Company : With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality ma...

blank
With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermedia...
With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.
blank

02

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

UQUIFA

With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.

About the Company : With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality ma...

blank
With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermedia...
With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.
blank

03

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

UQUIFA

With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.

About the Company : With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality ma...

blank
With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermedia...
With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.
blank

04

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

UQUIFA

With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.

About the Company : With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality ma...

blank
With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermedia...
With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.
blank

05

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

UQUIFA

With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.

About the Company : With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality ma...

blank
With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermedia...
With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.
blank

06

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

UQUIFA

With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.

About the Company : With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality ma...

blank
With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermedia...
With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.
blank

07

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

UQUIFA

With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.

About the Company : With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality ma...

blank
With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermedia...
With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.
blank

08

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

UQUIFA

With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.

About the Company : With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality ma...

blank
With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermedia...
With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.
blank

09

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

UQUIFA

With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.

About the Company : With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality ma...

blank
With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermedia...
With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.
blank

10

26th North American ISSX
Not Confirmed
arrow
arrow
26th North American ISSX
Not Confirmed

UQUIFA

With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.

About the Company : With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality ma...

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

Brand Name : N/A

26th North American ISSX
Not Confirmed
arrow

Brand Name : N/A

arrow
26th North American ISSX
Not Confirmed

UQUIFA

Dosage Form : Capsule

Dosage Strength : 30mg

Packaging :

Brand Name :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Spain

blank

02

Brand Name : N/A

26th North American ISSX
Not Confirmed
arrow

Brand Name : N/A

arrow
26th North American ISSX
Not Confirmed

UQUIFA

Dosage Form : Capsule

Dosage Strength : 60mg

Packaging :

Brand Name :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Spain

blank

03

Brand Name : N/A

26th North American ISSX
Not Confirmed
arrow

Brand Name : N/A

arrow
26th North American ISSX
Not Confirmed

UQUIFA

Dosage Form : Tablet

Dosage Strength : 100mg

Packaging :

Brand Name :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Europe

blank

04

Brand Name : N/A

26th North American ISSX
Not Confirmed
arrow

Brand Name : N/A

arrow
26th North American ISSX
Not Confirmed

UQUIFA

Dosage Form : Tablet

Dosage Strength : 150mg

Packaging :

Brand Name :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Europe

blank

05

Brand Name : N/A

26th North American ISSX
Not Confirmed
arrow

Brand Name : N/A

arrow
26th North American ISSX
Not Confirmed

UQUIFA

Dosage Form : Parenteral

Dosage Strength : 2mg/ ml

Packaging :

Brand Name :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Europe

blank

06

Brand Name : N/A

26th North American ISSX
Not Confirmed
arrow

Brand Name : N/A

arrow
26th North American ISSX
Not Confirmed

UQUIFA

Dosage Form : Film Coated Tablet

Dosage Strength : 600mg

Packaging :

Brand Name :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Europe

blank

07

Brand Name : N/A

26th North American ISSX
Not Confirmed
arrow

Brand Name : N/A

arrow
26th North American ISSX
Not Confirmed

UQUIFA

Dosage Form : Capsule

Dosage Strength : 20mg

Packaging :

Brand Name :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Europe

blank

08

Brand Name : N/A

26th North American ISSX
Not Confirmed
arrow

Brand Name : N/A

arrow
26th North American ISSX
Not Confirmed

UQUIFA

Dosage Form : Capsule

Dosage Strength : 40mg

Packaging :

Brand Name :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Europe

blank

09

Brand Name : N/A

26th North American ISSX
Not Confirmed
arrow

Brand Name : N/A

arrow
26th North American ISSX
Not Confirmed

UQUIFA

Dosage Form : Film Coated Tablet

Dosage Strength : 20mg

Packaging :

Brand Name :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Europe

blank

10

Brand Name : N/A

26th North American ISSX
Not Confirmed
arrow

Brand Name : N/A

arrow
26th North American ISSX
Not Confirmed

UQUIFA

Dosage Form : Film Coated Tablet

Dosage Strength : 40mg

Packaging :

Brand Name :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Europe

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Services

Upload your portfolio for free, ask us

Analytical

Click here to discover the service providers for Analytical

API Manufacturing

Click here to discover the service providers for API Manufacturing

API & Drug Product Development

Click here to discover the service providers for API & Drug Product Development

API Development

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Sales, Marketing, Registration

Click here to discover the service providers for Sales, Marketing, Registration

Inspections and registrations

Upload your audits for free, ask us

GDUFA

read-more
read-more

01

GDUFA fees paid

USA
26th North American ISSX
Not Confirmed
arrow

GDUFA fees paid

USA
arrow
26th North American ISSX
Not Confirmed

API Manufacturer : API MANUFACTURE

FDF Manufacturer :

Facility Name : Union Quimico Farmaceutica

Business Address : Poligono Industrial Moli de ...

FEI Number : 3002808431

Country : Spain

Paid in : 2021

blank

02

GDUFA fees paid

USA
26th North American ISSX
Not Confirmed
arrow

GDUFA fees paid

USA
arrow
26th North American ISSX
Not Confirmed

API Manufacturer : API MANUFACTURE

FDF Manufacturer :

Facility Name : Union Quimico Farmaceutica SA

Business Address : Avenida Puigcerda, 9 C-17, K...

FEI Number : 3002808427

Country : Spain

Paid in : 2021

blank

03

GDUFA fees paid

USA
26th North American ISSX
Not Confirmed
arrow

GDUFA fees paid

USA
arrow
26th North American ISSX
Not Confirmed

API Manufacturer : API MANUFACTURE

FDF Manufacturer :

Facility Name : UQUIFA Mexico, S.A. de C.V.

Business Address : Calle 37 Este No. 126 Jiutep...

FEI Number : 1000260514

Country : Spain

Paid in : 2021

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Contact UQUIFA and get a quotation

UQUIFA is a supplier offers 106 products (APIs, Excipients or Intermediates).

Find a price of Ciprofloxacin bulk with DMF, CEP, JDMF offered by UQUIFA

Find a price of Clindamycin Phosphate bulk with DMF, CEP, JDMF offered by UQUIFA

Find a price of Ketoconazole bulk with DMF, CEP, JDMF offered by UQUIFA

Find a price of Lansoprazole bulk with DMF, CEP, JDMF offered by UQUIFA

Find a price of Metformin bulk with DMF, CEP, JDMF offered by UQUIFA

Find a price of Omeprazole bulk with CEP, JDMF offered by UQUIFA

Find a price of Aciclovir bulk with DMF, CEP offered by UQUIFA

Find a price of Allopurinol bulk with DMF, CEP offered by UQUIFA

Find a price of Cimetidine bulk with DMF, CEP offered by UQUIFA

Find a price of Doxylamine Succinate bulk with DMF, CEP offered by UQUIFA

Find a price of Famotidine bulk with DMF, CEP offered by UQUIFA

Find a price of Nimodipine bulk with DMF, CEP offered by UQUIFA

Find a price of Pantoprazole Sodium bulk with DMF, CEP offered by UQUIFA

Find a price of Quetiapine Hemifumarate bulk with DMF, CEP offered by UQUIFA

Find a price of Sitagliptin Phosphate bulk with DMF, CEP offered by UQUIFA

Find a price of Solifenacin Succinate bulk with DMF, CEP offered by UQUIFA

Find a price of Terbinafine Hydrochloride bulk with DMF, JDMF offered by UQUIFA

Find a price of Tolterodine Tartrate bulk with DMF, CEP offered by UQUIFA

Find a price of Carisoprodol bulk with DMF offered by UQUIFA

Find a price of Esomeprazole Magnesium bulk with DMF offered by UQUIFA

Find a price of Esomeprazole Sodium bulk with CEP offered by UQUIFA

Find a price of Lamotrigine bulk with CEP offered by UQUIFA

Find a price of Minocycline Hydrochloride bulk with CEP offered by UQUIFA

Find a price of Quetiapine Hemifumarate bulk with CEP offered by UQUIFA

Find a price of Ranitidine Hydrochloride bulk with DMF offered by UQUIFA

Find a price of Zolpidem Tartrate bulk with CEP offered by UQUIFA

Find a price of Albendazole bulk with DMF offered by UQUIFA

Find a price of Bicalutamide bulk with DMF offered by UQUIFA

Find a price of Cinacalcet Hydrochloride bulk with DMF offered by UQUIFA

Find a price of Ciprofloxacin Hydrochloride bulk with DMF offered by UQUIFA

Find a price of Clindamycin Phosphate bulk offered by UQUIFA

Find a price of Cyclopentolate Hydrochloride bulk with DMF offered by UQUIFA

Find a price of Duloxetine Hydrochloride bulk with CEP offered by UQUIFA

Find a price of Ketorolac Trometamol bulk offered by UQUIFA

Find a price of Levofloxacin bulk with DMF offered by UQUIFA

Find a price of Mivacurium Chloride bulk with DMF offered by UQUIFA

Find a price of Nitrendipine bulk with CEP offered by UQUIFA

Find a price of Omeprazole bulk with DMF offered by UQUIFA

Find a price of Omeprazole Sodium bulk with JDMF offered by UQUIFA

Find a price of Pyrantel Pamoate bulk with DMF offered by UQUIFA

Find a price of Pyrantel Tartrate bulk with DMF offered by UQUIFA

Find a price of Ranolazine bulk with DMF offered by UQUIFA

Find a price of Rivaroxaban bulk with DMF offered by UQUIFA

Find a price of Telmisartan bulk with DMF offered by UQUIFA

Find a price of Tropicamide bulk with DMF offered by UQUIFA

Find a price of 2-Isopropyl-4-Methylaminomethyl-Thiazole bulk offered by UQUIFA

Find a price of Bupropion Hydrochloride bulk offered by UQUIFA

Find a price of Carisoprodol bulk offered by UQUIFA

Find a price of Cilostazol bulk offered by UQUIFA

Find a price of Ciprofloxacin Hydrochloride bulk offered by UQUIFA

Find a price of Clindamycin Hydrochloride bulk offered by UQUIFA

Find a price of Doxylamine Succinate bulk offered by UQUIFA

Find a price of Duloxetine Hydrochloride bulk offered by UQUIFA

Find a price of Fluoxetine Hydrochloride bulk offered by UQUIFA

Find a price of Gatifloxacin bulk offered by UQUIFA

Find a price of Iopamidol bulk offered by UQUIFA

Find a price of L-VALINE bulk offered by UQUIFA

Find a price of Labetalol Hydrochloride bulk offered by UQUIFA

Find a price of Linezolid bulk offered by UQUIFA

Find a price of Meloxicam bulk offered by UQUIFA

Find a price of Memantine Hydrochloride bulk offered by UQUIFA

Find a price of Modafinil bulk offered by UQUIFA

Find a price of Nelfinavir Mesylate bulk offered by UQUIFA

Find a price of Omeprazole bulk offered by UQUIFA

Find a price of Omeprazole Magnesium bulk offered by UQUIFA

Find a price of Rabeprazole bulk offered by UQUIFA

Find a price of Ranitidine bulk offered by UQUIFA

Find a price of Ranitidine Hydrochloride bulk offered by UQUIFA

Find a price of Risedronate Sodium bulk offered by UQUIFA

Find a price of Valacyclovir Hydrochloride bulk offered by UQUIFA

Find a price of Venlafaxine Hydrochloride bulk offered by UQUIFA

Find a price of Zolpidem Tartrate bulk offered by UQUIFA

Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES OF CIMETIDINE USP IN BARCELONA, SPAIN. bulk offered by UQUIFA

Find a price of FLUOROSULFONYLETHANONE bulk offered by UQUIFA

Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN BARCELONA, SPAIN. bulk offered by UQUIFA

Find a price of 2,4-WING ACTIVE ESTER bulk offered by UQUIFA

Find a price of Apixaban bulk offered by UQUIFA

Find a price of Benzydamine Hydrochloride bulk offered by UQUIFA

Find a price of Bilastine bulk offered by UQUIFA

Find a price of Brexpiprazole bulk offered by UQUIFA

Find a price of Brivaracetam bulk offered by UQUIFA

Find a price of Cariprazine Hydrochloride bulk offered by UQUIFA

Find a price of Crisaborole bulk offered by UQUIFA

Find a price of Dabigatran Etexilate Mesylate bulk offered by UQUIFA

Find a price of Edoxaban Tosylate bulk offered by UQUIFA

Find a price of Elagolix Sodium bulk offered by UQUIFA

Find a price of Esketamine Hydrochloride bulk offered by UQUIFA

Find a price of Etofenamate bulk offered by UQUIFA

Find a price of Hydroxychloroquine Sulphate bulk offered by UQUIFA

Find a price of Hydroxyzine Dihydrochloride bulk offered by UQUIFA

Find a price of Hydroxyzine Pamoate bulk offered by UQUIFA

Find a price of Ketamine Hydrochloride bulk offered by UQUIFA

Find a price of Lasmiditan bulk offered by UQUIFA

Find a price of Lesinurad bulk offered by UQUIFA

Find a price of Levofloxacin Hemihydrate bulk offered by UQUIFA

Find a price of Mirabegron bulk offered by UQUIFA

Find a price of Morantel Tartrate bulk offered by UQUIFA

Find a price of Oxantel Pamoate bulk offered by UQUIFA

Find a price of Oxibendazole bulk offered by UQUIFA

Find a price of Pethidine Hydrochloride bulk offered by UQUIFA

Find a price of Pimavanserin Tartrate bulk offered by UQUIFA

Find a price of Propofol bulk offered by UQUIFA

Find a price of Ricobendazole bulk offered by UQUIFA

Find a price of Robenidine HCl bulk offered by UQUIFA

Find a price of Tavaborole bulk offered by UQUIFA

Find a price of Ursodeoxycholic Acid bulk offered by UQUIFA

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty